The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie


GALLIVAC IBD

. Lyophilisate for suspension

Boehringer Ingelheim Vetmedica GmbHVPA10454/057/001

Main Information

Trade NameGALLIVAC IBD
Active SubstancesInfectious bursal disease virus, attenuated strain S706
Strength.
Dosage FormLyophilisate for suspension
Licence HolderBoehringer Ingelheim Vetmedica GmbH
Licence NumberVPA10454/057/001

Group Information

ATC CodeQI01AD09 avian infectious bursal disease virus (gumboro disease)
Therapeutic ClassImmunological - Live Vaccine
SpeciesChickens

Status

Authorised/WithdrawnAuthorised
Licence Issued21/12/2006
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back